Table 1 Base case
Variable | Base case | Valor high | Valor low | References |
|---|---|---|---|---|
Cost US$ | ||||
Cost Budesonide-Formoterol (per 120 doses) | $53 | $66 | $40 | |
Cost controlled (anual) | $416 | $520 | $312 | [17] |
Cost mild exacerbation (per episode) | $94 | $118 | $71 | |
Cost moderate exacerbation (per episode) | $191 | $239 | $143 | |
Cost severe exacerbation (per episode) | $386 | $483 | $290 | |
Utilities (anual) | ||||
Controlled asthma | 0.92 | 1 | 0.69 | |
Exacerbation with OCS Burst | 0.86 | 1 | 0,65 | [13] |
Exacerbation with ED visit | 0,83 | 1 | 0,62 | |
Exacerbation with Hospitalization | 0.74 | 0.93 | 0.56 | |
Budesonide + Formoterol efect | ||||
Relative risk on exacerbation rate | 0.85 | 0.72 | 1 | |
Relative risk on ED visit | 0.65 | 0.43 | 0.98 | [9] |
Adherence to as need—budesonide-formoterol | 68% | 85% | 51% | [10] |
Adherence to IC daily | 62% | 78% | 47% | [10] |
As-Needed budesonide-formoterol by Time of Day | 0.52 | 0.65 | 0.39 | |
Transition probabilities | ||||
Probability controlled to OC Burst | 0.11 | 0.14 | 0.10 | |
Probability OCS Burst to ED visit | 0.02 | 0.03 | 0.02 | [12] |
Probability of ED visti to hospitalization | 0.0117 | 0.01 | 0.01 | |
Asthma mortality | 0.0000020 | 0.00 | 0.00 | |
Annual dicount rate | 5% | 6% | 0% | |